iRhythm announces results of four studies to be unveiled at American Heart Association Scientific Sessions
iRhythm to present multiple abstracts at the American Heart Association 2022 Scientific Sessions event
iRhythm Technologies will have the results of four studies presented by leading clinical investigators at the American Heart Association’s 2022 Scientific Sessions on Nov. 5-7 in Chicago, Illinois. The studies listed below focus on iRhythm’s core suite of Zio XT and AT patch-based extended and mobile cardiac monitoring products and services.
Saturday, Nov. 5
- 3:00 – 4:00 p.m. CDT – SA4182: “Ascension Health System Experience With Extended Ambulatory Electrocardiographic Monitoring: Implementation of a Novel Integrated Approach to Better Characterize Disparities in Healthcare.” Presenter: Robert A. Pickett, MD, Cardiac Electrophysiologist, Ascension Saint Thomas Heart.
Sunday, Nov. 6
- 10:30 – 11:30 a.m. CDT – SU3161: “Cost-Effectiveness of AF Screening With 2-Week Patch Monitors: The mHealth Screening To Prevent Strokes Study.” Presenter: Dr. Matthew R. Reynolds, Cardiac Electrophysiologist, Lahey Hospital & Medical Center and Baim Institute for Clinical Research.
Monday, Nov. 7
- 1:45 – 2:45 p.m. CDT – MO4131: “Near-Real Time Extended Ambulatory ECG Monitoring in Patients With Syncope Unveils a Spectrum of Arrhythmias and High Incidence of Atrial Fibrillation.” Presenter: Dr. Bobbi L. Hoppe, Cardiac Electrophysiologist, Kittitas Valley Healthcare.
- 1:45 – 2:45 p.m. CDT – MO4134: “Assessing the Optimal Duration of ECG Monitoring Required to Accurately Establish PVC Burden in a Large National Database.” Presenter: Dr. Andrew K. Krumerman, Cardiac Electrophysiologist and Professor of Medicine, Albert Einstein College of Medicine.
“As an industry leader, iRhythm is committed to rigorously generating high-quality clinical and scientific evidence to serve our patients and the field,” said Dr. Mintu Turakhia, chief medical officer and chief scientific officer at iRhythm. “These studies will add to the robust body of evidence for our product portfolio, will continue to drive our own innovation, and will advance the understanding of arrhythmia diagnosis and care for clinicians.”
Visit the AHA 2022 Scientific Sessions website to register.